A patient with known diabetes presents with a random blood glucose of 628 mg/dL and otherwise normal parameters; how should this patient be managed?

Management of Blood Glucose 628 mg/dL in Known Diabetic Patient

Immediately initiate insulin therapy with a target glucose range of 140-180 mg/dL, using either continuous intravenous insulin infusion if the patient is critically ill or scheduled subcutaneous basal-bolus insulin if non-critically ill. 1

Immediate Assessment Required

First, determine the patient's clinical status and rule out life-threatening hyperglycemic emergencies:

• Check for diabetic ketoacidosis (DKA): Measure serum ketones (beta-hydroxybutyrate preferred), venous pH, bicarbonate, and anion gap 2
• Check for hyperosmolar hyperglycemic state (HHS): Measure serum osmolality (>320 mOsm/L indicates HHS), electrolytes, and assess mental status 3
• Assess hydration status: Severe dehydration suggests HHS, particularly in Type 2 diabetes 3

Critical pitfall: At glucose levels >300 mg/dL (16.7 mmol/L), you must systematically investigate for ketosis in Type 1 diabetics and insulin-treated Type 2 diabetics 3. In Type 2 diabetes, this level should also raise suspicion for hyperosmolar coma, which presents deceptively with variable symptoms like fatigue, mild confusion, and dehydration 3.

Treatment Algorithm

If DKA or HHS is Present:

• Transfer to ICU immediately 3
• Start continuous IV insulin infusion
• Initiate aggressive fluid resuscitation
• Follow specific DKA/HHS protocols 2

If No DKA/HHS (Patient is Stable):

For Non-Critically Ill Patients (most common scenario):

1. Start scheduled subcutaneous insulin immediately - this is the preferred approach over sliding scale alone 4, 1

2. Initial insulin dosing:

   • If insulin-naive: Start 0.5-1 units/kg/day divided as 50% basal insulin and 50% rapid-acting insulin 3
   • If already on insulin: Continue home regimen but increase doses based on hospital requirements 1

3. Basal-bolus regimen structure 4:

   • Basal insulin: Long-acting insulin (glargine, detemir, or degludec) once or twice daily
   • Prandial insulin: Rapid-acting analog (lispro, aspart, or glulisine) before each meal
   • Correction insulin: Additional rapid-acting insulin for glucose >180 mg/dL

4. Add rapid-acting insulin and ensure good hydration immediately 3

For Critically Ill Patients:

• Start continuous IV insulin infusion when glucose >180 mg/dL 4
• Target range: 140-180 mg/dL 4
• Use validated insulin infusion protocol 4

Monitoring Requirements

• Point-of-care glucose testing every 4-6 hours initially, then before meals and bedtime once stable 1
• Monitor for hypoglycemia closely - this is a major limiting factor 5
• Check electrolytes, particularly potassium, during initial management 2

Critical Management Principles

Avoid sliding scale insulin as monotherapy - this approach is strongly discouraged and associated with poor outcomes 4, 6. The evidence is clear that scheduled insulin (basal-bolus) is superior.

Target glucose range:

• Premeal: <140 mg/dL
• Random: <180 mg/dL 4, 1

More stringent targets (110-140 mg/dL) may be appropriate only if achievable without significant hypoglycemia risk 4.

Transition Planning

Once glucose is controlled:

• If on IV insulin, transition to subcutaneous insulin 1-2 hours before stopping the infusion 2, 7
• Convert at 60-80% of the 24-hour IV insulin dose as basal insulin 7
• Ensure discharge planning includes clear diabetes management instructions and outpatient follow-up within 1 month 7, 4

Key takeaway: At 628 mg/dL with otherwise normal parameters, this patient needs immediate insulin therapy with close monitoring for hyperglycemic emergencies, but can likely be managed on a general medical floor with scheduled subcutaneous insulin unless signs of DKA/HHS develop.